Celldex Therapeutics, Inc
Veridion Score
Composite trend over time
Why is CLDX moving today?
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CLDX.
CLDX insider activity
Celldex Therapeutics, Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$475K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-01-06 | 2026-01-02 | Martin Samuel Bates | Insider | buy | $10.38 | 4,817 | 32,942 | $50K | SEC Form 4 |
| 2025-12-17 | 2025-12-15 | PEPIN RONALD | Insider | buy | $2.78 | 11,000 | 20,097 | $31K | SEC Form 4 |
| 2025-12-17 | 2025-12-15 | PEPIN RONALD | Insider | buy | $9.02 | 8,333 | 9,097 | $75K | SEC Form 4 |
| 2025-12-08 | 2025-12-04 | Jimenez Freddy A. | Insider | sell | $29.09 | 4,166 | 30,796 | $121K | SEC Form 4 |
| 2025-11-17 | 2025-11-13 | Wright Richard M. | Insider | sell | $24.00 | 49,298 | 20,833 | $1.2M | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 5 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moCLDX contract awards, year to date.
Public federal awards linked to this ticker.
CLDX lobbying filings, year to date.
Registered lobbying filings matched to Celldex Therapeutics, Inc.